Epigenetic and Chromatin Alterations in Myeloid Malignancies: From MDS to AML
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 23
Special Issue Editor
Special Issue Information
Dear Colleagues,
Myeloid neoplastic diseases are heterogenous clonal disorders of mutant hematopoietic stem and progenitor cells, and are caused by various mutated genes encoding tumor suppressors, transcription factors, components of the splicesome, epigenetic modifying enzymes, components of the cohesin complex and cohesin-regulating proteins. The development of blood cancer is also associated with genomic translocations. In recent years, disordered chromatin organization has emerged as a new determinant of the pathogenesis of Acute Myelodysplastic Syndrome (MDS) and its consequent progression into Acute Myeloid Leukemia (AML). Thus, this Special Issue, entitled "Epigenetic and Chromatin Alterations in Myeloid Malignancies: From MDS to AML", will focus on the mechanism implicated in leukemogenesis in myeloid neoplasia, namely the involvement of chromatinopathy. This Special Issue could be extended to lymphoid neoplastic diseases.
Dr. Mineko Terao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myelodysplastic syndrome
- acute myeloid leukemia
- epigenetics
- chromatin alterations
- leukemogenesis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
